Angiotensin-(1-7) as an antihypertensive, antifibrotic target

Current Hypertension Reports

Volumn 10, Issue 3, 2008, Pages 227-232

  Katovich, Michael J ^a   Grobe, Justin L ^b   Raizada, Mohan K ^b  

^a UNIVERSITY OF FLORIDA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN RECEPTOR ANTAGONIST; ANGIOTENSIN[1-7]; ANGIOTENSIN[1-7][7 DEXTRO ALANINE]; BRADYKININ; CANDESARTAN; DEOXYCORTICOSTERONE ACETATE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HEPTAPEPTIDE; INDOMETACIN; N ETHYLCARBAMOYL 3 [4 (5 FORMYL 4 METHOXY 2 PHENYL 1 IMIDAZOLYLMETHYL)PHENYL] 5 ISOBUTYL 2 THIOPHENESULFONAMIDE; NITRIC OXIDE;

ANTIHYPERTENSIVE ACTIVITY; BLOOD PRESSURE REGULATION; DRUG TARGETING; EX VIVO STUDY; GENOMICS; HEART PROTECTION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SIGNAL TRANSDUCTION;

ANGIOTENSIN I; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; BRADYKININ; CARDIOTONIC AGENTS; FIBRINOLYTIC AGENTS; HUMANS; HYPERTENSION; NITRIC OXIDE; PEPTIDE FRAGMENTS; RECEPTORS, CELL SURFACE; RENIN-ANGIOTENSIN SYSTEM; SIGNAL TRANSDUCTION;

EID: 56349087447     PISSN: 15226417     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11906-008-0043-9     Document Type: Review

References (50)

1. Santos RA, Brosnihan KB, Chappell MC, et al.: Converting enzyme activity and angiotensin metabolism in the dog brainstem. Hypertension 1988, 11(2 Pt 2):I153-I157.
2. Schiavone MT, Santos RAS, Brosnihan KB, et al.: Release of vasopressin from the rat hypothalamo-neurohypophysial system by angiotensin-(1-7) heptapeptide. Proc Natl Acad Sci U S A 1988, 85:4095-4098.
3. Ferrario CM: Biological roles of angiotensin-(1-7). Hypertens Res 1992, 15:61-66.
4. Welches WR, Santos RA, Chappell MC, et al.: Evidence that prolyl endopeptidase participates in the processing of brain angiotensin. J Hypertens 1991, 9:631-638.
5. Yamamoto K, Chappell MC, Brosnihan KB, et al.: In vivo metabolism of angiotensin I by neutral endopeptidase (EC 3.4.24.11) in spontaneously hypertensive rats. Hypertension 1992, 19(6 Pt 2):692-696.
6. Donoghue M, Hsieh F, Baronas E, et al.: Acton S. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ Res 2000, 87:1-9.
7. Tipnis SR, Hooper NM, Hyde R, et al.: A human homolog of angiotensin-converting enzyme. J Biol Chem 2000, 275; 33238-33243.
8. Trask AJ, Ferrario CM: Angiotensin-(1-7): pharmacology and new perspectives in cardiovascular treatments. Cardiovasc Drug Rev 2007, 25:162-174.
9. Ferrario CM: Angiotensin-converting enzyme 2 and angiotensin-(1-7): an evolving story in cardiovascular regulation. Hypertension 2006, 47:515-521.
10. Chappell MC, Pirro NT, Sykes A, et al.: Metabolism of angiotensin-(1-7) by angiotensin converting enzyme. Hypertension 1998, 31(1 Pt 2):362-367.
11. Luque M, Martin P, Martell N, et al.: Effects of captopril related to increased levels of prostacyclin and angiotensin-(1-7) in essential hypertension. J Hypertens 1996, 14:799-805.
12. Campbell DJ, Kladis A, Duncan AM: Effects of converting enzyme inhibitors on angiotensin and bradykinin peptides. Hypertension 1994, 23:439-449.
13. Wei CC, Ferrario CM, Brosnihan KB, et al.: Angiotensin peptides modulate bradykinin levels in the interstitium of the dog heart in vivo. J Pharmacol Exp Ther 2002, 300:324-329.
14. Ferrario CM, Jessup J, Chappell MC, et al.: Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. Circulation 2005, 111:2605-2610.
15. Ishiyama Y, Gallagher PE, Averill DB, et al.: Upregulation of angiotensin-converting enzyme 2 after myocardial infarction by blockade of angiotensin II receptors. Hypertension 2004, 43:970-976.
16. Igase M, Strawn WB, Gallagher PE, et al.: Angiotensin II AT1 receptors regulate ACE2 and angiotensin-(1-7) expression in the aorta of spontaneously hypertensive rats. Am J Physiol Heart Circ Physiol 2005, 289:H1013-H1019.
17. Benter IF, Diz DI, Ferrario CM: Cardiovascular actions of angiotensin-(1-7). Peptides 1993, 14:679-684.
18. Benter IF, Ferrario CM, Morris M, et al.: Antihypertensive actions of angiotensin-(1-7) in spontaneously hypertensive rats. Am J Physiol 1995, 269:H313-H319.
19. Santos RAS, Campagnole-Santos MJ, Baracho NCV, et al.: Characterization of a new angiotensin antagonist selective for angiotensin-(1-7): evidence that the actions of angiotensin-(1-7) are mediated by specific angiotensin receptors. Brain Res Bull 1994, 35:293-298.
20. Moriguchi A, Tallant EA, Matsumura K, et al.: Opposing actions of angiotensin-(1-7) and angiotensin II in the brain of transgenic hypertensive rats. Hypertension 1995, 25:1260-1265.
21. Iyer SN, Chappell MC, Averill DB, et al.: Vasodepressor actions of angiotensin-(1-7) unmasked during combined treatment with lisinopril and losartan. Hypertension 1998, 31:699-705.
22. Iyer SN, Averill DB, Chappell MC, et al.: Contribution of angiotensin-(1-7) to blood pressure regulation in salt-depleted hypertensive rats. Hypertension 2000, 36:417-422.
23. Bayorh MA, Eatman D, Walton M, et al.: 1A-779 attenuates angiotensin-(1-7) depressor response in salt-induced hypertensive rats. Peptides 2002, 23:57-64.
24. Paula RD, Lima CV, Khosla MC, et al.: Angiotensin-(1-7) potentiates the hypotensive effect of bradykinin in conscious rats. Hypertension 1995, 26(Pt 2):1154-1159.
25. Lima CV, Paula RD, Resende FL, et al.: Potentiation of the hypotensive effect of bradykinin by short-term infusion of angiotensin-(1-7) in normotensive and hypertensive rats. Hypertension. 1997, 30(3 Pt 2):542-548.
26. Widdop RE, Sampey DB, Jarrott B.: Cardiovascular effects of angiotensin-(1-7) in conscious spontaneously hypertensive rats. Hypertension. 1999, 34:964-968.
27. Walters PE, Gaspari TA, Widdop RE: Angiotensin-(1-7) acts as a vasodepressor agent via angiotensin II type 2 receptors in conscious rats. Hypertension 2005, 45:960-966.
28. Mahon JM, Carr RD, Nicol AK, et al.: Angiotensin-(1-7) is an antagonist at the type 1 angiotensin II receptor. J Hypertens 1994, 12:1377-1381.
29. Zhu Z, Zhong J, Zhu S, et al.: Angiotensin-(1-7) inhibits angiotensin II-induced signal transduction. J Cardiovasc Pharmacol 2002, 40:693-700.
30. Wang LJ, He JG, Ma H, et al: Chronic administration of angiotensin-(1-7) attenuates pressure-overload left ventricular hypertrophy and fibrosis in rats. Di Yi Jun Yi Da Xue Xue Bao 2005, 25:481-487.
31. Yamada K, Iyer SN, Chappell MC, et al.: Converting enzyme determines plasma clearance of angiotensin-(1-7). Hypertension 1998, 32:496-502.
32. Ferrario CM, Chappell MC, Tallant EA, et al.: Counter-regulatory actions of angiotensin-(1-7). Hypertension 1997, 30(Pt 2):535-541.
33. Iyer SN, Chappell MC, Brosnihan KB, et al.: Role of AT1 and AT2 receptors in the plasma clearance of angiotensin II. J Cardiovasc Pharmacol 1998, 31:464-469.
34. Weber KT, Brilla CG: Pathological hypertropby and cardiac interstitium. Fibrosis and renin-angiotensin-aldosterone system. Circulation 1991, 83:1849-1865.
35. Burrell LM, Risvanis J, Kubota E, et al.: Myocardial infarction increases ACE2 expression in rat and humans. Eur Heart J. 2005, 26(4):369-75.
36. Averill DB, Ishiyama Y, Chappell MC, et al.: Cardiac angiotensin-(1-7) in ischemic cardiomyopathy. Circulation 2003, 108:2141-2146.
37. Zisman LS, Keller RS, Weaver B, et al.: Increased angiotensin-(1-7)-forming activity in failing human heart ventricles: evidence for upregulation of the angiotensin-converting enzyme homologue ACE2. Circulation 2003, 108:1707-1712.
38. Grobe JL, Mecca AP, Lingis M, et al.: Prevention of angiotensin II-induced cardiac remodeling by angiotensin-(1-7). Am J Physiol Heart Circ Physiol 2007, 292:H736-H742.
39. Grobe JL, Mecca AP, Mao H, et al.: Chronic angiotensin-(1-7) prevents cardiac fibrosis in DOCA-salt model of hypertension. Am J Physiol Heart Circ Physiol 2006, 290: H2417-H2423.
40. Loot AE, Roks AJ, Henning RH, et al.: Angiotensin-(1-7) attenuates the development of heart failure after myocardial infarction in rats. Circulation 2000, 105:1548-1550.
41. Santos RA, Ferreira AJ, Nadu AP, et al.: Expression of an angiotensin-(1-7)-producing fusion protein produces cardioprotective effects in rats. Physiol Genomics 2004, 17:292-299.
42. Ferreira AJ, Oliveira TL, Castro MC, et al.: Isoproterenol-induced impairment of heart function and remodeling are attenuated by the nonpeptide angiotensin-(1-7) analogue AVE 0991. Life Sci 2007, 81:916-923.
43. Santos RA, Castro CH, Gava E, et al.: Impairment of in vitro and in vivo heart function in angiotensin-(1-7) receptor MAS knockout mice. Hypertension 2006, 47:996-1002.
44. Iwata M, Cowling RT, Gurantz D, et al.: Angiotensin-(1-7) binds to specific receptors on cardiac fibroblasts to initiate anti-fibrotic and anti-trophic effects. Am J Physiol Heart Circ Physiol 2005, 289:H2356-H2363.
45. Tallant EA, Ferrario CM, Gallagher PE: Angiotensin-(1-7) inhibits growth of cardiac myocytes through activation of the mas receptor. Am J Physiol Heart Circ Physiol 2005, 289:H1560-H1566.
46. Huentelman MJ, Grobe JL, Vazquez J, et al.: Protection from angiotensin II-induced cardiac hypertrophy and fibrosis by systemic lentiviral delivery of ACE2 in rats. Exp Physiol 2005, 90:783-790.
47. Díez-Freire C, Vázquez J, Correa de Adjounian MF, et al.: ACE2 gene transfer attenuates hypertension-linked pathophysiological changes in the SHR. Physiol Genomics 2006, 27:12-19.
48. Yamazato M, Yamazato Y, Sun C, et al.: Overexpression of angiotensin-converting enzyme 2 in the rostral ventrolateral medulla causes long-term decrease in blood pressure in the spontaneously hypertensive rats. Hypertension 2007, 49:926-931.
49. Huentelman MJ, Zubcevic J, Hernández Prada JA, et al.: Structure-based discovery of a novel angiotensin-converting enzyme 2 inhibitor. Hypertension 2004, 44:903-906.
50. Wessel N, Malberg H, Heringer-Walther S, et al.: The angiotensin-(1-7) receptor agonist AVE0991 dominates the circadian rhythm and baroreflex in spontaneously hypertensive rats. J Cardiovasc Pharmacol 2007, 49:67-73.